Figure Legends

**Figure 1.** Time-concentration curve data of edelfosine after a single intravenous administration of edelfosine loaded (A) Compritol® and (B) Precirol® LN to BALB/c mice (n=8, mean ± S.D.)

**Figure 2.** Tissue/plasma concentration ratios of edelfosine after a single intravenous dose of edelfosine-loaded Compritol® and Precirol® LN to BALB/c mice (n=8)

**Figure 3.** Time-plasma concentration curve data of edelfosine obtained with the WinNonLin program after a single oral administration of edelfosine solution and edelfosine loaded Compritol® and Precirol® LN to mice (n=8 per group, mean ± SD)

**Figure 4.** Tissue/plasma concentration ratios of edelfosine after a single oral dose of edelfosine-loaded Compritol® and Precirol® LN to BALB/c mice (n=8 per group, mean ± SD) (*p<0.05; **p<0.01 by Student’s t test)

**Figure 5.** Differences in A) volume and B) weight of implanted mantle-cell lymphoma xenograft tumors 20 days after a treatment of daily PBS (control), daily edelfosine solution (30 mg/kg bw) and Compritol® and Precirol® LN every four days (30 mg/kg bw) (n=8 per group, mean ± SD). *p<0.05; **p<0.01 by Student’s t test

**Figure 6.** Representation of the antimetastatic efficacy of LN, expressed as the measurement of the volume of metastatic nodes, 20 days after a treatment of daily PBS (control), daily edelfosine solution (30 mg/kg bw) and Compritol® and Precirol® LN every four days (30 mg/kg bw) (n=8 per group, mean ± SD). **p<0.01 by Student’s t test